The emerging landscape of immune cell therapies

EW Weber, MV Maus, CL Mackall - Cell, 2020 - cell.com
Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …

Manufacturing chimeric antigen receptor T cells: issues and challenges

C Roddie, M O'Reilly, JDA Pinto, K Vispute, M Lowdell - Cytotherapy, 2019 - Elsevier
Clinical trials of adoptively transferred CD19 chimeric antigen receptor (CAR) T cells have
delivered unprecedented responses in patients with relapsed refractory B-cell malignancy …

Emerging strategies in TCR-engineered T cells

F Wei, XX Cheng, JZ Xue, SA Xue - Frontiers in immunology, 2022 - frontiersin.org
Immunotherapy of cancer has made tremendous progress in recent years, as demonstrated
by the remarkable clinical responses obtained from adoptive cell transfer (ACT) of patient …

Mixed T cell receptor dimers harbor potentially harmful neoreactivity

MM van Loenen, R de Boer, AL Amir… - Proceedings of the …, 2010 - National Acad Sciences
Adoptive transfer of T cell receptor (TCR)-transduced T cells may be an attractive strategy to
target both hematological malignancies and solid tumors. By introducing a TCR, large …

Adoptive cell therapy for cancer treatment

S Du, J Yan, Y Xue, Y Zhong, Y Dong - Exploration, 2023 - Wiley Online Library
Adoptive cell therapy (ACT) is a rapidly growing anti‐cancer strategy that has shown
promise in treating various cancer types. The concept of ACT involves activating patients' …

Adoptive immunotherapy for cancer

M Ruella, M Kalos - Immunological reviews, 2014 - Wiley Online Library
Recent clinical success has underscored the potential for immunotherapy based on the
adoptive cell transfer (ACT) of engineered T lymphocytes to mediate dramatic, potent, and …

Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR

S Okamoto, J Mineno, H Ikeda, H Fujiwara… - Cancer research, 2009 - AACR
Adoptive T-cell therapy using lymphocytes genetically engineered to express tumor antigen-
specific TCRs is an attractive strategy for treating patients with malignancies. However, there …

Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells

D Sommermeyer, W Uckert - The Journal of Immunology, 2010 - journals.aai.org
TCR gene therapy using adoptive transfer of TCR gene-modified T cells is a new strategy for
treatment of cancer. One critical prerequisite for TCR gene therapy is sufficient expression of …

Off-the-shelf allogeneic T cell therapies for cancer: opportunities and challenges using naturally occurring “universal” donor T cells

C Perez, I Gruber, C Arber - Frontiers in immunology, 2020 - frontiersin.org
Chimeric antigen receptor (CAR) engineered T cell therapies individually prepared for each
patient with autologous T cells have recently changed clinical practice in the management of …

CD3 limits the efficacy of TCR gene therapy in vivo

M Ahmadi, JW King, SA Xue, C Voisine… - Blood, The Journal …, 2011 - ashpublications.org
The function of T-cell receptor (TCR) gene modified T cells is dependent on efficient surface
expression of the introduced TCR α/β heterodimer. We tested whether endogenous CD3 …